87 related articles for article (PubMed ID: 12132871)
1. Breast cancer risk factors and HER2 over-expression in tumors.
Swede H; Moysich KB; Freudenheim JL; Quirk JT; Muti PC; Hurd TC; Edge SB; Winston JS; Michalek AM
Cancer Detect Prev; 2001; 25(6):511-9. PubMed ID: 12132871
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
[TBL] [Abstract][Full Text] [Related]
3. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women.
Nichols HB; Trentham-Dietz A; Love RR; Hampton JM; Hoang Anh PT; Allred DC; Mohsin SK; Newcomb PA
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):41-7. PubMed ID: 15668474
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and family history of cancer in women who have breast cancer.
Lehrer S; Lee P; Tartter P; Shank B; Brower ST
Mt Sinai J Med; 1995 Nov; 62(6):415-8. PubMed ID: 8692153
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
7. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers.
McTiernan A; Thomas DB; Johnson LK; Roseman D
J Natl Cancer Inst; 1986 Oct; 77(4):849-54. PubMed ID: 3463818
[TBL] [Abstract][Full Text] [Related]
10. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
11. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases as late breast cancer relapse. Single institution experience and review of the literature.
Tomasevic Z; Radosevic-Jelic Lj; Jovanovic D; Milovanovic Z; Tomasevic ZM; Jelic S; Borojevic N
J BUON; 2009; 14(2):225-8. PubMed ID: 19650170
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer.
Horiguchi J; Koibuchi Y; Iijima K; Yoshida T; Yoshida M; Takata D; Oyama T; Iino Y; Morishita Y
Int J Mol Med; 2003 Dec; 12(6):855-9. PubMed ID: 14612957
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
Taniyama K; Ishida K; Toda T; Motoshita J; Kuraoka K; Saito A; Tani Y; Uike T; Teramoto S; Koseki M
Breast Cancer; 2008; 15(3):231-40. PubMed ID: 18264744
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women.
Terry MB; Gammon MD; Schoenberg JB; Brinton LA; Arber N; Hibshoosh H
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1100-3. PubMed ID: 12376514
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer and risk factors in an African population: a case referent study.
Amir H; Makwaya CK; Aziz MR; Jessani S
East Afr Med J; 1998 May; 75(5):268-70. PubMed ID: 9746995
[TBL] [Abstract][Full Text] [Related]
19. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies.
Ma H; Bernstein L; Pike MC; Ursin G
Breast Cancer Res; 2006; 8(4):R43. PubMed ID: 16859501
[TBL] [Abstract][Full Text] [Related]
20. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
